The class action lawsuit adds legal overhang to an already distressed equity. Combined with the recent $150M dilutive offering and the FDA CRL, the risk profile is highly negative. Monitor for any settlement announcements or further adverse regulatory developments, and watch for the lead plaintiff deadline on October 5, 2026.
Price Chart
Executive Summary
Robbins LLP has announced a securities class action lawsuit against Replimune Group (REPL), alleging the company misled investors about the efficacy and viability of its lead product candidate RP1. The lawsuit stems from the FDA's April 2026 Complete Response Letter (CRL) rejecting the BLA for RP1 in combination with nivolumab, which caused the stock to collapse from $4.76 to $1.70 per share. This litigation introduces legal overhang and potential liability, compounding the bearish sentiment from the recent dilutive $150M offering filed 11 days ago.
Key Facts
- A securities class action has been filed against Replimune Group (REPL) for alleged misrepresentations regarding its lead product candidate RP1.
- The class period is October 20, 2025 to April 10, 2026.
- The FDA issued a Complete Response Letter (CRL) on April 10, 2026, rejecting the BLA for RP1 in combination with nivolumab for advanced melanoma.
- The FDA stated the submitted studies (RPL-001-16 and RP1-104) did not meet evidentiary standards for regulatory approval.
- The stock fell 19.46% on April 10, 2026, to $4.76, and then an additional 64.29% on April 13, 2026, to $1.70 per share.
- Lead plaintiff deadline is October 5, 2026.
- This filing follows a $150M dilutive offering (424B5) filed on August 10, 2026, which added ~13% dilution.
Financial Impact
Stock declined from $4.76 to $1.70 per share (cumulative ~71% drop) following the CRL announcement. Potential liability from the class action is undisclosed.
Risk Factors
- Potential financial liability from the securities class action lawsuit.
- Further stock price decline due to ongoing litigation and regulatory uncertainty.
- Dilution from the recent $150M offering compounds existing financial distress.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302857491 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $14.71 $13.07 | ▲ +11.15% | ▲ +11.16% | $13.04 (+11.35%) |
Aug 19, 2026 6w ago | Insider Cluster | $14.05 $13.07 | ▼ −6.98% | ▼ −6.98% | $13.04 (−7.19%) |
Aug 14, 2026 7w ago | 8-K | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 14, 2026 7w ago | Press Release | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 10, 2026 7w ago | Press Release | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 8-K | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 424B5 | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 7, 2026 8w ago | 8-K | $12.06 $15.04 | ▲ +24.71% | ▲ +25.11% | $13.04 (+8.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access